Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
about
Cardiac Dysfunction Among Ugandan HIV-infected Children on Antiretroviral Therapy.Rational design of drugs that induce human immunodeficiency virus replication.Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IkappaB kinase inhibitor.Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitisDevelopment of HIV reservoir targeted long acting nanoformulated antiretroviral therapiesTenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.Dynamics of viral and proviral loads of feline immunodeficiency virus within the feline central nervous system during the acute phase following intravenous infection.Protein Kinase C: One Pathway towards the Eradication of Latent HIV-1 Reservoirs.Recent advances in the treatment of HIV/AIDS.Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid AssemblyDual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.IL-7 as a potential therapy for HIV-1-infected individuals.Identification of T cell-signaling pathways that stimulate latent HIV in primary cells.HIV-specific cellular immune responses are stimulated by structured treatment interruption in chronically HIV-1 infected KoreansHomodimers of the Antiviral Abacavir as Modulators of P-glycoprotein Transport in Cell Culture: Probing Tether Length.Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infectionSurface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy.Comparison of transcriptional profiles between CD4+ and CD8+ T cells in HIV type 1-infected patientsThe viral protein Tat can inhibit the establishment of HIV-1 latency.Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.Discovering regulated networks during HIV-1 latency and reactivation.Primary cell model for activation-inducible human immunodeficiency virusA hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation.Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia.Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis.Investigation of oral bioavailability and brain distribution of the Ind(8)-Val conjugate of indinavir in rodents.
P2860
Q30362434-52783A90-674E-45F7-A027-EC937025EC9CQ34229958-6A378B89-46D6-48EB-8D63-D9108BF44BB6Q34352092-FCB7A5DA-E9DF-4B88-9F1D-14FFE886312DQ34761828-31896175-4C59-4BDB-9B12-C8DAE42AFB0DQ34797004-12F5A821-9166-4F10-930D-85F468BD9CC3Q35043368-9B470650-6823-4157-8840-7BD40F01A049Q35149650-59EFBA1E-DB5F-478A-A686-7712A74C12A1Q35830264-A0B1018F-BA82-4907-AFCC-0A8EEE041682Q35917365-F335F2B5-2ACA-477C-AAE2-3813E33928F0Q36030091-AFDA1E42-3A7A-4E68-95EB-153B329846CBQ36266486-01BFF5E8-60A9-46B8-96A6-E1C11938108DQ36299926-4DD58146-6A76-43D4-A933-BB81CF22312CQ36690000-739D86FE-B408-4CA9-BD30-9CC5C76E2B38Q37205311-4210200C-2AEA-45F6-A0C1-E6CEF10556DAQ37323391-B2EE04BA-9151-41CA-BC11-3C1CADE06C88Q37484850-797D48A3-75BC-4C11-A3CF-60A4DAB6238EQ37639557-54100086-60F8-4C1C-96A8-591A30A4BCDBQ37780687-667C39E8-87C8-434C-973C-096592EC0581Q39369490-2E4B5B70-63E1-4C30-A99A-0830A4D96C15Q39413458-1EC3C854-3C7F-40EE-90CD-27001A3EF668Q39997616-424813A1-4DD9-47E1-84FF-29199D21F083Q40210426-4040FA73-3E47-48A8-95FB-9A812CF24C9AQ42093067-08A6245C-0D49-4E41-8DE2-80B7B5F98909Q42227130-0DDD7E27-43F0-494E-8BEA-D6A86B837746Q42561269-A8D933C8-A731-49A2-B86C-FEA8F383B7ABQ44065007-B4EEA8D5-1A05-413C-B2F0-7EB3B81536E7Q46438449-171459A1-1AAA-43CD-BD51-ED21A1317A6A
P2860
Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Reservoirs of human immunodefi ...... bstacles to viral eradication.
@en
type
label
Reservoirs of human immunodefi ...... bstacles to viral eradication.
@en
prefLabel
Reservoirs of human immunodefi ...... bstacles to viral eradication.
@en
P2860
P356
P1476
Reservoirs of human immunodefi ...... bstacles to viral eradication.
@en
P2093
Roger J Pomerantz
P2860
P356
10.1086/338256
P407
P577
2001-11-21T00:00:00Z